Trial
NCT02771626
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Calithera Biosciences, Inc
Collaborators
—
Condition
Clear Cell Renal Cell Carcinoma (ccRCC)
Intervention
CB-839
Why stopped
lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-03-17